MedTrace Logo

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

NCT01242514 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1917

Last updated 2014-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).

Conditions

Interventions

DRUG

Fostamatinib

Fostamatinib 100mg twice daily

DRUG

Fostamatinib

Fostamatinib 150mg once daily

DRUG

Fostamatinib

Fostamatinib 100mg once daily

Sponsors & Collaborators

Principal Investigators

  • Chris O'Brien, MD PhD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • Colombia
  • Czechia
  • Estonia
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Mexico
  • Peru
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242514 on ClinicalTrials.gov